Search Within

Advanced Practice Providers

  1. "Lymphoma"
Formats
  1. Meeting Abstract (71)
  2. Journal Article (32)
  3. Research Letter (2)
Groups
  1. Center for Hematologic Malignancies (105)
  2. Department of Medicine (105)
  3. Hematologic Malignancies, Division of (105)
  4. Lymphoma (105)
  5. Nursing (76)
  6. Survivorship Research (70)

More Groups

People
  1. Maria Palomba (61)
  2. Alison Moskowitz (50)
  3. Andrew Zelenetz (48)
  4. Steven Horwitz (43)
  5. Ariela Noy (42)
  6. Paul Hamlin (38)

More People

Years
  1. 2025 (2)
  2. 2024 (3)
  3. 2023 (10)
  4. 2022 (8)
  5. 2021 (19)
  6. 2020 (11)

More Years

Publications
  1. Blood (51)
  2. Hematological Oncology (9)
  3. Journal of Clinical Oncology (7)
  4. Biology of Blood and Marrow Transplantation (5)
  5. Blood Advances (4)
  6. Leukemia and Lymphoma (3)

More Publications

Publishers
  1. American Society of Hematology (55)
  2. Wiley Blackwell (10)
  3. American Society of Clinical Oncology (8)
  4. Elsevier Inc. (8)
  5. American Association for Cancer Research (4)
  6. Nature Publishing Group (4)

More Publishers

Results (105)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-δ,γ inhibitor, in combination with romidepsin or bortezomib in relapsed/refractory T-cell lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Koch, R.; Mehta-Shah, N.; Myskowski, P.; Kheterpal, M.; Dogan, A.; Davey, T.; Galasso, N.; Evan, M.; Shah, M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A Phase I study of ibrutinib combined with rituximab, ifosfamide, carboplatin, and etoposide in patients with relapsed or primary diffuse large B-cell lymphoma
    Meeting Abstract

    Sauter, C. S.; Matasar, M. J.; Schoder, H.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Implication of rituximab priming practices
    Meeting Abstract

    Laudati, C.; Clark, C.; Sumka, J.; Timoney, J.; Hamlin, P.
    Oncology Nursing Forum (2017)

    Fulltext@MSK | Save
  • Development of a geriatric service in a cancer center: Lessons learned
    Journal Article

    Korc-Grodzicki, B.; Tew, W.; Hurria, A.; Yulico, H.; Lichtman, S.; Hamlin, P.; Bosl, G.
    Journal of Oncology Practice (2017)

    Fulltext@MSK | Save
  • A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M.; Lynch, P.; Scheuerman, M.; Kumar, A.; Gerecitano, J. F.; Zelenetz, A. D.; Hamlin, P. A. Jr; Noy, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Risk factors predicting outcomes for primary refractory Hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation
    Journal Article

    Shah, G. L.; Yahalom, J.; Matasar, M. J.; Verwys, S. L.; Goldman, D. A.; Bantilan, K. S.; Zhang, Z.; McCall, S. J.; Moskowitz, A. J.; Moskowitz, C. H.
    British Journal of Haematology (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schöder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save